Avid Bioservices Inc (CDMO)

[biopharm]

Maybe BDO can advise the IIS and market makers that their valuation of some IP assets / CDMO manufacturing etc and related M/A for life sciences are looking astronomically higher than expected

Patti Seymour will be with Avid Bioservices event Dec 3, 2019

Dec 3, 2019 from 10:00 AM to 2:00 PM EST

Technical Seminar
Speaker:

Patti Seymour Managing Director, BioProcess Technology Group - BDO USA, LLP

Dr. Hugh Davis Chief Business Officer - Frontage Laboratories, Inc.

Richard Richieri Chief Operations Officer - Avid Bioservices, Inc.

Dr. Arugadoss Devakumar Director, Analytical Development - Avid Bioservices, Inc.

Location:
Massachusetts Biotechnology Council

_____

TECHNOLOGY TRANSFER OF NOVEL IMMUNOTHERAPY PROGRAM: GVAX AND CRS-207


By: Patti Seymour

Presented at:
IBC’s BioPharmaceutical Development and Production Week; 2014 Mar 24-27; San Diego, CA.

Aduro BioTech is developing novel and complex immunotherapeutics for the treatment of oncology and infectious disease indications. This talk describes a case study for the selection of CMOs and technology transfer for Aduro’s lead clinical immunotherapy, which combines GVAX, a GM-CSF expressing tumor cell line and CRS-207, a live attenuated double deleted Listeria strain, in preparation for pivotal clinical trials. It covers the initial gap assessment process, CMO selection process and how the gap assessment was used to prioritize the technology transfer activities to ensure the knowledge and experience gained during development and early clinical manufacturing is effectively transferred. It concludes with lessons learned from the entire process.


https://www.bptc.com/technology-transfer-novel-immunotherapy-program-gvax-crs-207/

_______

Patti Seymour is back again, aligned with Avid Bioservices ...maybe those IIS will continue to find it a bit more difficult to collect CDMO shares

Who knows what we don't know....though BDO knows also how big PS Targeting is ...as it leads many to know the correct protein pathways to go after


Laura Hix Glickman - Nov 2012 to June 2017 Aduro

Bill Hanson - July 2009 to Dec 2018 Aduro

Chris Rae - July 2013 to Feb 2018 Aduro

Christopher Thanos - Sutro to Halozyme to Actym

________

BDO and you, stronger together.

BDO offers life science organizations a broad range of support, both for their current and potential government award portfolios in biodefense and pandemic response funded by:
Department of Health and Human Services (HHS)
Office of the Assistant Secretary for Preparedness and Response (ASPR)
Biomedical Advanced Research and Development Authority (BARDA)
Strategic National Stockpile (SNS)
National Institutes of Health (NIH)
Centers for Disease Control and Prevention (CDC)
Department of Defense (DOD)
Defense Threat Reduction Agency (DTRA)
Department of Homeland Security (DHS)


https://www.bdo.com/industries/life-sciences/bio-defense

______


BDO USA Acquires BioProcess Technology Consultants to Expand Product Development Advisory Services in Life Sciences

April 01, 2019 09:05 AM EST

https://www.businesswire.com/news/home/20190401005081/en/BDO-USA-Acquires-BioProcess-Technology-Consultants-Expand

_______

BDOs Merger, Growth into Biopharmaceuticals Explained

April 23, 2019 by INSIDE Public Accounting

In light of BDOs recent acquisition of BioProcess Technology Consultants (BPTC), INSIDE Public Accounting asked leaders from both firms to discuss further expansion within the life sciences industry, growth strategies and how the merger will help clients.
BPTC is a chemistry, manufacturing and controls consulting service. Chicago-based BDO (FY18 net revenue of $1.46 billion) sees the merger as expanding its existing services in developing new biopharmaceutical products while minimizing risk.
IPA spoke with Eric Jia-Sobota, national leader of BDOâ??s Industry Specialty Services and Life Sciences practices, and Howard Levine, Ph.D., managing director and national leader of the Bioprocess Technology Group within BDOs Life Sciences practice.

IPA: Its starting to become more common for accounting and advisory firms to acquire consulting firms, but often they are related to technology, such as cybersecurity. Acquiring a consultancy related to the biopharmaceutical industry is unusual. Why the interest?

Jia-Sobota: Our clients frequently look to leverage the industry experience and client-specific insights our collective team has, including in the life sciences realm. The life sciences industry is an important vertical for BDO especially as technologys infiltration of the space continues to create both new opportunities and mirroring risks.

For instance, while breakthroughs in CAR-T and other cell gene therapies have huge potential, biopharmaceutical manufacturers cant neglect investment in their manufacturing processes as demand for biopharmaceuticals continues to rise. While it may be tempting to invest in new facilities to alleviate production capacity shortages, in the long term, companies must invest in new technologies and methods for bioprocessing.
Biopharmaceutical manufacturers need to develop cost-effective methods for scaling their operations, or else lose a competitive edge to those whose investments in technology and new processes make their therapies more affordable. The addition of BPTC enhances our ability to help biopharmaceutical manufacturers meet these evolving demands and de-risk product development while at the same time capitalizing on new, tech-enabled opportunities to further improve patient outcomes.

IPA: What was so attractive about BioProcess Technology Consultants that made BDO pull the trigger on an acquisition?

Jia-Sobota: BDO and BPTCâ??s technical and operational services to life sciences entities are complementary, with a focus on helping organizations navigate risk, make informed investment decisions and seize new opportunities. The addition of BPTC supports the continued growth and diversification of life sciences capabilities at BDO.

IPA: How will this acquisition help BDO clients? Can you give me an example?

Levine: The addition of BPTC enhances BDOs ability to advise clients on technical, strategic and regulatory aspects of biopharmaceutical development at all stages in the product lifecycle. For instance, there is growing concern within the biopharma sector that current processes and facilities may not have capacity to meet rising global demand for high-volume biologics. Through the addition of BPTC, BDO can further assist companies in implementing process intensification practices that can help bridge the gap between supply and demand, while also improving process efficiency and even product quality.

IPA: BPTC founder Howard L. Levine is quoted as saying his firm helped companies address "unmet medical needs and increase patient access to novel medicines." How so?

Levine: While emerging technologies and innovations like CAR-T therapies and others show promise for treating formerly intractable diseases or injuries, rising costs limit their accessibility for patients. The professionals from BPTC who have joined BDO will complement our ability to help clients ensure the long-term success of therapies by helping them improve their cost-effectiveness while maintaining or improving efficacy. This may include developing and implementing process intensification strategies â?? such as continuous bioprocessing.

IPA: How does this acquisition fit into BDOs growth strategy?

Jia-Sobota: The addition of BPTC aligns with recent investments BDO has made in innovation across the firm â?? including added resources in technology solutions, digital transformation, risk advisory and data privacy. These additions position us well for continued growth in the coming years and align with our commitment to offering our clients a comprehensive suite of services across both industry agnostic and specific business imperatives.

IPA: What can clients expect in the future in terms of additional acquisitions like this one?

Jia-Sobota: As part of our commitment to client service, we are continuing to make investments in innovation that can bolster the support we provide clients across industries.

http://blog.insidepublicaccounting.com/2019/04/bdos-merger-growth-into-biopharmaceuticals-explained/

_________